ESMO Gastrointestinal Cancers Congress | Conference

CRC Patients With Liver Metastasis Receive Unanticipated Benefit From SIRT

July 6th 2017

While expected improvements in survival did not emerge with SIRT plus chemotherapy, an unanticipated benefit was observed with SIRT in patients with metastatic colorectal cancer.

Dr. Argiles on Study of Carcinoembryonic Antigen T-Cell Bispecific Antibody

July 5th 2017

Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses a carcinoembryonic antigen T-cell bispecific antibody.

Dr. O'Neil Discusses Napabucasin With FOLFIRI and Bevacizumab in CRC

July 5th 2017

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses napabucasin with FOLFIRI and bevacizumab (Avastin) in colorectal cancer.

Expert Discusses Surgical Intervention in Metastatic CRC

July 2nd 2017

In a central evaluation for surgical treatment options in the FIRE-3 study results, investigators set out to determine the number of patients with metastatic colorectal cancer who had resectable disease during systemic first-line therapy.

Dr. Lenz Discusses Immunotherapy in Gastrointestinal Cancers

July 1st 2017

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses immunotherapy in gastrointestinal cancers.

Dr. Schmoll Discusses CHARTA Results in CRC

July 1st 2017

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the results of the CHARTA study in colorectal cancer.

Napabucasin Clinically Active in Both Pancreatic and Colon Cancer

July 1st 2017

The novel stemness inhibitor napabucasin in combination with different standard chemotherapy backbones demonstrated promising activity in metastatic pancreatic adenocarcinoma and metastatic colorectal cancer.

Novel Bispecific Antibody Effective for Heavily Pretreated mCRC

July 1st 2017

CEA-TCB showed a favorable safety profile and promising efficacy in patients with heavily-pretreated microsatellite stable metastatic colorectal cancer, with enhanced efficacy when combined with atezolizumab.

Liquid Biopsies Identify Mechanisms of Resistance in Gastrointestinal Cancers

July 1st 2017

Aparna Parikh, MD, discusses the potential impact of liquid biopsies in overcoming resistance to targeted therapies in gastrointestinal cancer.

Occurrence of Hand-Foot Skin Response May Signal Regorafenib Activity in Hepatocellular Carcinoma

June 30th 2017

Patients with unresectable HCC continue to show statistically significant improvement in overall survival with second-line regorafenib (Stivarga) treatment.

Advanced Age Presents No Barrier to Successful Nivolumab Treatment in HCC

June 30th 2017

Durable responses and improved long-term survival were demonstrated with nivolumab (Opdivo) that were not altered by the age of patients with advanced hepatocellular carcinoma across all age groups of patients participating in the CheckMate 040 trial.

Dr. Saab on Napabucasin With Gemcitabine and Nab-Paclitaxel in Pancreatic Adenocarcinoma

June 30th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses napabucasin with gemcitabine and nab-paclitaxel in pancreatic adenocarcinoma.

Dr. Parikh Discusses Liquid Biopsies in Gastrointestinal Cancers

June 30th 2017

Aparna R. Parikh, MD, medical oncologist, Massachusetts General Hospital, discusses liquid biopsies in gastrointestinal cancers.

Expert Discusses Tumor Location and Mutational Status in CRC

June 30th 2017

Julien Taieb, MD, discusses the prognostic value of primary tumor location in colon cancer.

HA Levels Predict PEGPH20 Response in Metastatic Pancreatic Cancer

June 29th 2017

The addition of pegvorhyaluronidase alfa (PEGPH20) to standard nab-paclitaxel/gemcitabine improved progression-free survival over standard therapy in patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Hendifar on the HALO-202 Study in Metastatic Pancreatic Ductal Adenocarcinoma

June 29th 2017

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses HALO-202 in metastatic pancreatic ductal adenocarcinoma.

Dr. Bruix Discusses the Updated Findings of the RESORCE Trial in HCC

June 29th 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the updated findings of the RESORCE Trial in hepatocellular carcinoma.

AM0010 Plus FOLFOX Shows Promise in Metastatic Pancreatic Cancer

June 29th 2017

Combination therapy with AM0010, a PEGylated human interleukein (IL)-10, plus fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) demonstrated encouraging clinical activity in metastatic pancreatic ductal adenocarcinoma.

Dr. Heinemann on the Use of Depth of Response and RECIST in CRC

October 24th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, compares the use of depth of response and RECIST criteria to measure responses in patients with colorectal cancer.

Dr. Dicato on Agents to Treat Thrombocytopenia for Patients With Cancer

July 21st 2016

Mario Dicato, MD, Hematology-Oncology Service, Centre Hospitalier de Luxembourg, discusses 3 agents used for the treatment or reduction of thrombocytopenia for patients with cancer.